Drug intelligence / Profile preview

NeuraWell treatment-resistant anxiety drug

Development stage: Preclinical
Lead developer: NeuraWell Therapeutics

Overview

NeuraWell Therapeutics is developing an unnamed drug candidate for the treatment of treatment-resistant anxiety. The compound is designed to target a neurotransmitter system known to regulate anxiety through a unique mechanism of action, distinguishing it from current standard-of-care treatments. It is intended for use as either a monotherapy or as an augmenting agent to existing anti-anxiety medications. As of early 2024, the specific molecular target, modality, and clinical development phase have not been publicly disclosed by the company.

Beyond the preview

Go deeper on NeuraWell treatment-resistant anxiety drug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuraWell treatment-resistant anxiety drug.

Explore the full profile